Patent ID: 8637453

Claim:
A compound selected from compounds of the following formula, and pharmaceutically acceptable salts thereof: wherein: —R 1 is —R 1A ; —R 1A is -iPr; —R 2 is —H; —R 3 is —H; —R 4 is —R 4A ; —R 4A is -Me; —R 5 is —H; —R 6 is —H; —R 7 is independently —R 7A or —R 7B ; —R 7A is -tBu; —R 7B is -L 7B1 -R 7BB ; -L 7B1 is —CH 2 —; —R 7BB is —R 7BB1 ; —R 7BB1 is phenyl; —R 8 is —H; and wherein: —R 9 is —H; —R 10 is —R 10A ; —R 10A is phenyl, and is optionally substituted with one or more substituents —R X3 ; or: —R 9 is —H; —R 10 is —R 10B ; —R 10B is pyridyl, and is optionally substituted with one or more substituents —R X3 ; or: —R 9 is —H; —R 10 is —R 10D ; —R 10D is independently piperidinyl, morpholinyl, or piperizinyl, and is optionally substituted with one or more substituents selected from C 1-4 alkyl; or: —R 9 is —H; —R 10 is —R 10B ; —R 10B is independently indazolyl, benzimidazolyl, benzothiazolyl, quinolinyl, or isoquinolinyl, and is optionally substituted with one or more substituents —R X3 ; or: the group —N(R 9 )—C(═O)—R 10 is the following group: and wherein: —R 11 is independently —R 11A or —R 11B ; —R 11A is -L Z -R Z4 ; -L Z - is —CH 2 —; —R Z4 is phenyl, and is optionally substituted with one or more substituents —R X3 ; —R 11B is —CR J1 R J2 —C(═O)—NR J3 R J4 ; —R J1 is —H; —R J2 is —H; —R J3 is independently —H or saturated aliphatic C 1-4 alkyl; —R J4 is independently —H or saturated aliphatic C 1-4 alkyl; or —NR J3 R J4 is pyrrolidino, piperidino, morpholino, or piperizino, and is optionally substituted with one or more substituents selected from C 1-4 alkyl; or —NR J3 R J4 is 1,2,3,4-tetrahydro-4-isoquinolin-2-yl, and is optionally substituted, with one or more substituents selected from C 1-4 alkyl; and —R 12 is —H; and wherein each —R X3 is independently selected from: —F, —Cl, —Br, —I, —R V , —CN, —OH, —OR V , —NH 2 , —NHR V , —NR V 2 , pyrrolidino, piperidino, morpholino, piperizino, N—(C 1-4 alkyl)-piperizino, -L V -NH 2 , -L V -NHR V , -L V -NR V 2 , -L V -pyrrolidino, -L V -piperidino, -L V -morpholino, -L V -piperizino, -L V -{N—(C 1-4 alkyl)-piperizino}, —C(═O)OH, —C(═O)OR V , —C(═O)NH 2 , —C(═O)NHR V , —C(═O)NR V 2 , —NHC(═O)NH 2 , —S(═O) 2 NH 2 , —S(═O) 2 NHR V , —S(═O) 2 NR V 2 , and ═O; and additionally, two adjacent groups —R X3 may together form —OCH 2 O—, —OCH 2 CH 2 O—, —CH 2 OCH 2 — or —OCH 2 CH 2 —; wherein: each -L V - is saturated aliphatic C 1-4 alkylene; and each —R V is saturated aliphatic C 1-4 alkyl.